- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc stock price live, this page displays NASDAQ CRVS stock exchange data. View the CRVS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Corvus Pharmaceuticals Inc real time stock price chart below.
What Is the Corvus Pharmaceuticals Inc Stock Price Today?
The Corvus Pharmaceuticals Inc stock price today is 13.330.
What Is the Stock Symbol for Corvus Pharmaceuticals Inc?
The stock symbol for Corvus Pharmaceuticals Inc is "CRVS."
What Stock Exchange Does Corvus Pharmaceuticals Inc Trade On?
Corvus Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Corvus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Corvus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRVS quote. (ISIN: US2210151005)
What Is the Corvus Pharmaceuticals Inc Stock Price Today?
The Corvus Pharmaceuticals Inc stock price today is 13.330.
What Is the Stock Symbol for Corvus Pharmaceuticals Inc?
The stock symbol for Corvus Pharmaceuticals Inc is "CRVS."
What Stock Exchange Does Corvus Pharmaceuticals Inc Trade On?
Corvus Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Corvus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Corvus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRVS quote. (ISIN: US2210151005)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.950
13.905
52 wk Range
5.640
26.950
CRVS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.95013.905
52 wk Range
5.64026.950
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRVS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
33.143
Upside
+148.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Corvus publishes soquelitinib data in Blood journal- Investing.com
- Corvus publishes soquelitinib data in Blood journal
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.143
(+148.63% Upside)
Corvus Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Q2 net loss widened 125% to $18M as R&D expenses surged 102.5% to $16M, driven by accelerated clinical trials for lead drug soquelitinib.
- Cash position of $215.2M provides runway into Q2 2028, bolstered by $189.4M raised in Q1 2026 follow-on offering.
- Phase III PTCL interim futility analysis delayed to Q1 2027; atopic dermatitis SIERRA-1 top-line data expected Q3 2027.
- Shares fell 2.24% after-hours to $13.55 despite positive atopic dermatitis data showing durable benefit and no major safety concerns.
- Company expanding soquelitinib trials into asthma (late 2026) and hidradenitis suppurativa (Sept 2026) while exploring once-daily dosing.
Last Updated: 2026-08-06, 05:26 p/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.19 / -0.15
Revenue / Forecast
-- / --
Compare CRVS to Peers and Sector
Metrics to compare | CRVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRVSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −20.7x | −2.5x | −0.4x | |
PEG Ratio | −0.56 | −0.03 | 0.00 | |
Price/Book | 5.0x | 4.5x | 2.6x | |
Price / LTM Sales | - | 21.9x | 3.0x | |
Upside (Analyst Target) | 129.7% | 131.3% | 49.7% | |
Fair Value Upside | Unlock | 2.7% | 6.8% | Unlock |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Corvus Pharmaceuticals (CRVS) Stock Price Today?
The Corvus Pharmaceuticals stock price today is 13.330 USD.
What Stock Exchange Does Corvus Pharmaceuticals Trade On?
Corvus Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Corvus Pharmaceuticals?
The stock symbol for Corvus Pharmaceuticals is "CRVS."
What Is the Corvus Pharmaceuticals Market Cap?
As of today, Corvus Pharmaceuticals market cap is 1.120B USD.
What Is Corvus Pharmaceuticals's Earnings Per Share (TTM)?
The Corvus Pharmaceuticals EPS (TTM) is -0.625.
When Is the Next Corvus Pharmaceuticals Earnings Date?
Corvus Pharmaceuticals will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is CRVS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Corvus Pharmaceuticals Stock Split?
Corvus Pharmaceuticals has split 0 times.
How Many Employees Does Corvus Pharmaceuticals Have?
Corvus Pharmaceuticals has 37 employees.
What is the current trading status of Corvus Pharmaceuticals (CRVS)?
As of Sep 09, 2026, Corvus Pharmaceuticals (CRVS) is trading at a price of 13.330 USD, with a previous close of 13.930 USD. The stock has fluctuated within a day range of 12.950 USD to 13.905 USD, while its 52-week range spans from 5.640 USD to 26.950 USD.
What Is Corvus Pharmaceuticals (CRVS) Price Target According to Analysts?
The average 12-month price target for Corvus Pharmaceuticals is 33.143 USD, with a high estimate of 42 USD and a low estimate of 27 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +148.63% Upside potential.
What Is the CRVS Premarket Price?
CRVS's last pre-market stock price is 13.710 USD. The pre-market share volume is 439.000, and the stock has decreased by -0.220, or -1.580%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.